MOTS-c is the peptide research lead for insulin sensitivity. Administered mouse studies improved metabolic homeostasis and insulin resistance, and a 120-person placebo-controlled human trial now tests the question directly.
From mouse metabolism to a human insulin-sensitivity trial
Administered MOTS-c improved metabolic homeostasis and insulin resistance in mouse research. Human exercise physiology then showed that cycling increased endogenous MOTS-c in skeletal muscle and serum. Now a 120-person Phase 2a trial is testing 12 weeks of subcutaneous MOTS-c or placebo with OGTT-derived insulin sensitivity as the primary endpoint.
The trial has not posted results. That is the evidence boundary once—not the page thesis. The important story is that MOTS-c has advanced into a controlled human test of the exact metabolic outcome that made the peptide compelling.
What belongs in this collection
- MOTS-c: best matched to mitochondrial signaling and metabolic-fitness research.
- NAD+ formats: best matched to a direct NAD and cellular-energy routine.
- B12: best matched to a measured or strongly suspected B12 deficiency.
MOTS-c is the mitochondrial peptide in this set: a 16-amino-acid molecule encoded by a short open reading frame within mitochondrial 12S rRNA and detected in human skeletal muscle and circulation. Rebody's intended format is an injection vial. NAD+ and B12 address distinct pathways through their own formats, evidence, and instructions.
How the options differ
| Option | Biological question | Practical reason to choose it | Evidence boundary |
|---|---|---|---|
| MOTS-c injection | Mitochondrial signaling and insulin-sensitivity research | Closest experimental match to the query | the 120-person administered-human trial is recruiting with no results posted |
| NAD+ formats | NAD-dependent metabolism | Current route choices for a direct NAD+ routine | Not a demonstrated treatment for insulin resistance |
| Methylcobalamin B12 injection | Vitamin B12 deficiency | Appropriate when low B12 is a separate measured problem | It does not become a glucose treatment by appearing in this collection |
The routines differ across MOTS-c, NAD+, and B12. Preparation, storage, supplies, and refill timing can decide which biologically appropriate option becomes sustainable.
Why MOTS-c leads this search
Among MOTS-c, NAD+ formats, B12, MOTS-c leads because its molecule and evidence are closest to the shopper's question. The evidence is specific: In 10 young men, a stationary-bike session increased the body's own MOTS-c in skeletal muscle and serum. That was human exercise physiology, not treatment with a MOTS-c injection. Experiments that administered MOTS-c and improved physical-capacity or metabolic measures used mice. A recruiting Phase 2a trial plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and an OGTT-derived insulin-sensitivity endpoint. Results are not posted.
What the research measured
The key distinction is administration. Cycling increased the participants’ own MOTS-c in a study of 10 young men; the experiments that administered MOTS-c and improved physical-capacity or metabolic measures were performed in mice. The 120-person Phase 2a trial is recruiting and has posted no results.
Insulin sensitivity is the test, not the marketing phrase
The strongest reason MOTS-c belongs in this collection is the design of the recruiting Phase 2a trial. It plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and OGTT-derived insulin sensitivity as the primary endpoint. That is a direct administered-human question. Results are not posted.
Mouse research reported improved metabolic homeostasis and reduced insulin resistance after administered MOTS-c. The human cycling study showed that exercise changes endogenous MOTS-c. Those are separate lines of evidence and neither can stand in for the pending trial result.
Know which glucose measure answers which question
Fasting glucose is a snapshot. Hemoglobin A1c reflects a longer period. An oral glucose tolerance test shows the response to a defined glucose load. The trial’s OGTT-derived insulin-sensitivity endpoint is more specific than a wearable glucose trace or a post-meal feeling.
Weight and waist circumference are secondary endpoints in the trial, not proof that MOTS-c is a weight-loss drug. A change in glucose after a different meal is not an insulin-sensitivity result.
Where NAD+ and B12 fit
NAD+ is a direct coenzyme routine; it does not inherit MOTS-c’s trial endpoint. B12 is the answer when deficiency is documented, not a glucose treatment by association. If fatigue is the main symptom, clarify whether the actual question is metabolic, nutritional, sleep-related, medication-related, or something else.
The MOTS-c guide keeps chemical form, concentration, vial, schedule, supply, storage, and price together. B12 is $44.50 first month, then $89/month. NAD+ pricing depends on route.
Read the future result in the right order
When NCT07505745 reports, begin with enrollment and completion, not the headline. Check whether the randomized groups remained comparable, how much data were missing, and whether the prespecified analysis was followed. Then read the OGTT-derived primary endpoint: the size of the between-group difference, its uncertainty, and whether the result is clinically meaningful rather than merely statistically detectable.
Only after that should secondary outcomes enter the picture. Fasting glucose, insulin, HbA1c, weight, waist measures, tolerability, and discontinuations can add context, but a favorable secondary result does not rescue a failed primary endpoint. Subgroup findings—by sex, baseline insulin resistance, or another characteristic—need particular caution when the trial was not powered for them.
The population also controls the claim. This study plans 120 adults with prediabetes and overweight or obesity over 12 weeks. Even a positive result would not automatically establish prevention of diabetes, weight-loss efficacy, benefit in metabolically healthy athletes, or indefinite safety. It would answer a narrower and valuable question about administered MOTS-c in that defined population.
Until results are posted, standard glucose care keeps priority: validated testing, nutrition and activity changes that can be sustained, sleep, weight management when relevant, and prescribed therapy for diagnosed disease. “Mitochondrial” is not a reason to delay them.
Questions about MOTS-c and glucose metabolism
Why is insulin sensitivity the defining MOTS-c question?
Administered mouse studies reported improved insulin resistance and metabolic homeostasis, and the current 120-person human trial makes OGTT-derived insulin sensitivity its primary endpoint. The study is recruiting and has not posted results.
What exactly is the Phase 2 trial measuring?
Its primary endpoint is change in OGTT-derived insulin sensitivity after 12 weeks. It also includes metabolic, body-weight, waist, safety, laboratory, vital-sign, and ECG assessments.
Is MOTS-c a treatment for prediabetes?
The trial population includes adults with prediabetes and overweight or obesity, but enrollment criteria do not equal an approved indication or a positive result.
Will MOTS-c lower fasting glucose?
That outcome has not been established in administered-human research. Do not translate mouse metabolic findings into a promised fasting-glucose change.
Is MOTS-c a weight-loss peptide?
No human treatment result supports that label. Weight and waist are secondary trial endpoints; the primary question is insulin sensitivity.
Keep standard metabolic care visible
Nutrition, physical activity, sleep, medication, and established risk-factor treatment already have human evidence. A research peptide should not displace them while its decisive administered-human result remains pending.
Choose a baseline before starting any metabolic intervention and use the same laboratory method and timing for follow-up. Do not use a consumer wearable as a substitute for the ordered endpoint.
Antidoping and safety
MOTS-c is prohibited under the 2026 WADA list. The trial is collecting adverse events, laboratory data, vital signs, and ECG information because administered-human safety is part of the unanswered question.
Injection-site pain, redness, swelling, bruising, or infection are route concerns. Future product-specific exclusions and interactions must come from the finished label.
MOTS-c owns the insulin-sensitivity research lane
MOTS-c is the peptide-first choice for insulin-sensitivity research because the evidence has progressed from administered mouse metabolic findings and exercise-responsive human biology to a 120-person, 12-week controlled trial. The human result is pending; the direction of the research is already clear.
Keep reading
- Body-Composition Peptides for Muscle and Fat Metabolism
- Peptides for Metabolic Health After 40
- MOTS-C for Insulin Sensitivity and Weight Loss: What Phase 2 Is Testing